Effect of Nucleic Acid Amplification Testing on Population-Based Incidence Rates of Clostridium difficile Infection

被引：84

作者：

Gould, Carolyn V. ^{[1
]}

Edwards, Jonathan R. ^{[1
]}

Cohen, Jessica ^{[1
]}

Bamberg, Wendy M. ^{[2
]}

Clark, Leigh Ann ^{[3
]}

Farley, Monica M. ^{[3
,4
,5
]}

Johnston, Helen ^{[2
]}

Nadle, Joelle ^{[6
]}

Winston, Lisa ^{[7
]}

Gerding, Dale N. ^{[8
,9
]}

McDonald, L. Clifford ^{[1
]}

Lessa, Fernanda C. ^{[1
]}

机构：

[1] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA

[2] Colorado Dept Hlth, Denver, CO 80220 USA

[3] Georgia Emerging Infect Program, Atlanta, GA USA

[4] Emory Univ, Div Infect Dis, Atlanta, GA 30322 USA

[5] Atlanta VA Med Ctr, Atlanta, GA USA

[6] Calif Emerging Infect Program, Oakland, CA USA

[7] Univ Calif San Francisco, Div Infect Dis, San Francisco, CA 94143 USA

[8] Hines VA Hosp, Maywood, IL USA

[9] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA

来源：

CLINICAL INFECTIOUS DISEASES | 2013年 / 57卷 / 09期

关键词：

Clostridium difficile; clinical laboratory techniques; nucleic acid amplification techniques; incidence; surveillance; REAL-TIME PCR; ENZYME-IMMUNOASSAY; DIAGNOSIS; IMPACT; TOXIN; ASSAY;

D O I：

10.1093/cid/cit492

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Nucleic acid amplification testing (NAAT) is increasingly being adopted for diagnosis of Clostridium difficile infection (CDI). Data from 3 states conducting population-based CDI surveillance showed increases ranging from 43% to 67% in CDI incidence attributable to changing from toxin enzyme immunoassays to NAAT. CDI surveillance requires adjustment for testing methods.

引用

页码：1304 / 1307

页数：4

共 17 条

[1] Loop-Mediated Isothermal Amplification Compared to Real-Time PCR and Enzyme Immunoassay for Toxigenic Clostridium difficile Detection
Boyanton, Bobby L., Jr.
Sural, Preethi
Loomis, Caroline R.
Pesta, Christine
Gonzalez-Krellwitz, Laura
Robinson-Dunn, Barbara
Riska, Paul
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2012, 50 (03) : 640 - 645
[2] Centers for Disease Control and Prevention, Emerging infections program healthcare-associated infections-community interface report, Clostridioides difficile infection surveillance, 2021
[3] Clinical and laboratory evaluation of a real-time PCR for Clostridium difficile toxin A and B genes
de Jong, E.
de Jong, A. S.
Bartels, C. J. M.
van der Rijt-van den Biggelaar, C.
Melchers, W. J. G.
Sturm, P. D. J.
[J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2012, 31 (09) : 2219 - 2225
[4] Dudeck MA., 2013, Risk Adjustment for Healthcare Facility-Onset C. difficile and MRSA Bacteremia Laboratory-identified Event Reporting in NHSN
[5] Federal Register, FED REG, V76
[6] Public Reporting of Clostridium difficile and Improvements in Diagnostic Tests
Goldenberg, Simon D.
[J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2011, 32 (12) : 1231 - 1232
[7] Performance of Clostridium difficile Toxin Enzyme Immunoassay and Nucleic Acid Amplification Tests Stratified by Patient Disease Severity
Humphries, Romney M.
Uslan, Daniel Z.
Rubin, Zachary
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2013, 51 (03) : 869 - 873
[8] Clinical impact of switching conventional enzyme immunoassay with nucleic acid amplification test for suspected Clostridium difficile-associated diarrhea
Johnson, Steven W.
Kanatani, Meganne
Humphries, Romney M.
Uslan, Daniel Z.
[J]. AMERICAN JOURNAL OF INFECTION CONTROL, 2013, 41 (04) : 373 - 375
[9] Kandelaki G, 2011, INFECT CONT HOSP EP, V32, P932, DOI [10.1086/661788, 10.1086/661789]
[10] Impact of the Type of Diagnostic Assay on Clostridium difficile Infection and Complication Rates in a Mandatory Reporting Program
Longtin, Yves
Trottier, Sylvie
Brochu, Gilles
Paquet-Bolduc, Bianka
Garenc, Christophe
Loungnarath, Vilayvong
Beaulieu, Catherine
Goulet, Danielle
Longtin, Jean
[J]. CLINICAL INFECTIOUS DISEASES, 2013, 56 (01) : 67 - 73

← 1 2 →